Jacqueline E. Shea - 10 May 2024 Form 4 Insider Report for INOVIO PHARMACEUTICALS, INC. (INO)

Role
Chief Executive Officer, Director
Signature
/s/ Jacqueline E. Shea
Issuer symbol
INO
Transactions as of
10 May 2024
Net transactions value
-$25,475
Form type
4
Filing time
13 May 2024, 16:57:26 UTC
Previous filing
28 Feb 2024
Next filing
16 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INO Common Stock Options Exercise +5,500 +27% 26,012 10 May 2024 Direct F1, F2
transaction INO Common Stock Tax liability $25,475 -2,392 -9.2% $10.65 23,620 10 May 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INO Restricted Stock Unit Options Exercise $0 -5,500 -50% $0.000000 5,500 10 May 2024 Common Stock 5,500 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 16,500 restricted stock units is as follows: 5,500 shares vested on May 10, 2023; 5,500 shares vested on May 10, 2024; and 5,500 shares will vest on May 10, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
F2 Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.
F3 The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein.